Search hospitals > Tennessee > Knoxville

University of Tennessee Medical Center

Claim this profile
Knoxville, Tennessee 37920
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Melanoma
147 reported clinical trials
20 medical researchers
Photo of University of Tennessee Medical Center in KnoxvillePhoto of University of Tennessee Medical Center in KnoxvillePhoto of University of Tennessee Medical Center in Knoxville

Summary

University of Tennessee Medical Center is a medical facility located in Knoxville, Tennessee. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Melanoma and other specialties. University of Tennessee Medical Center is involved with conducting 147 clinical trials across 410 conditions. There are 20 research doctors associated with this hospital, such as Saikrishna Gadde, Timothy J. Panella, Radhakrishnan Ramchandren, M.D., and Neil E. Faulkner.

Area of expertise

1Cancer
Global Leader
University of Tennessee Medical Center has run 45 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2Breast Cancer
Global Leader
University of Tennessee Medical Center has run 30 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 negative
HER2 positive

Top PIs

Clinical Trials running at University of Tennessee Medical Center

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Bladder Carcinoma
Bladder Cancer
Gallbladder Cancer
Cancer
Renal Cell Carcinoma
Pancreatic Cancer
Small Cell Lung Cancer
Image of trial facility.

Imlunestrant

for Early Breast Cancer

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Recruiting2 awards Phase 36 criteria
Image of trial facility.

Sacituzumab Govitecan + Pembrolizumab

for Triple Negative Breast Cancer

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting2 awards Phase 36 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Tennessee Medical Center?
University of Tennessee Medical Center is a medical facility located in Knoxville, Tennessee. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Melanoma and other specialties. University of Tennessee Medical Center is involved with conducting 147 clinical trials across 410 conditions. There are 20 research doctors associated with this hospital, such as Saikrishna Gadde, Timothy J. Panella, Radhakrishnan Ramchandren, M.D., and Neil E. Faulkner.